β1- and β2-adrenergic receptor gene variation, β-blocker use and risk of myocardial infarction and stroke

American Journal of Hypertension

Volumn 21, Issue 3, 2008, Pages 290-296

  Lemaitre, Rozenn N ^a   Heckbert, Susan R ^b   Sotoodehnia, Nona ^a   Bis, Joshua C ^a   Smith, Nicholas L ^b,c   Marciante, Kristin D ^a   Hindorff, Lucia A ^a   Lange, Leslie A ^d   Lumley, Thomas S ^b   Rice, Kenneth M ^b   Wiggins, Kerri L ^a   Psaty, Bruce M ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ADULT; AGED; ALLELE; ARTICLE; CASE CONTROL STUDY; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; DRUG RECEPTOR BINDING; FEMALE; GENE INTERACTION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HEART INFARCTION; HETEROZYGOTE; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOLECULAR INTERACTION; PRIORITY JOURNAL; RECEPTOR GENE; STROKE; GENETICS; HAPLOTYPE; HYPERTENSION; MIDDLE AGED; RISK FACTOR; STATISTICAL MODEL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ADULT; AGED; ALLELES; CASE-CONTROL STUDIES; FEMALE; HAPLOTYPES; HUMANS; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RECEPTORS, ADRENERGIC, BETA-1; RECEPTORS, ADRENERGIC, BETA-2; RISK FACTORS; STROKE; TREATMENT OUTCOME; VARIATION (GENETICS);

EID: 40049098444     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1038/ajh.2007.71     Document Type: Article

References (24)

1. Ellison KE, Gandhi G. Optimising the use of β-adrenoceptor antagonists in coronary artery disease. Drugs 2005; 65:787-797.
2. Lindholm LH, Carlberg B, Samuelsson O. Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005; 366:1545-1553.
3. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, Lemaitre RN, Wagner EH, Furberg CD. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. JAMA 1997; 277:739-745.
4. Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, Weiss NS. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003; 289:2534-2544.
5. Psaty BM, Smith NL, Heckbert SR, Vos HL, Lemaitre RN, Reiner AP, Siscovick DS, Bis J, Lumley T, Longstreth WT Jr, Rosendaal FR. Diuretic therapy, the alpha-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002; 287:1680-1689.
6. Xiao RP, Zhu W, Zheng M, Cao C, Zhang Y, Lakatta EG, Han Q. Subtype-specific alpha1- and β-adrenoceptor signaling in the heart. Trends Pharmacol Sci 2006; 27:330-337.
7. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003; 43:381-411.
8. Heckbert SR, Hindorff LA, Edwards KL, Psaty BM, Lumley T, Siscovick DS, Tang Z, Durda JP, Kronmal RA, Tracy RP. β2-adrenergic receptor polymorphisms and risk of incident cardiovascular events in the elderly. Circulation 2003; 107:2021-2024.
9. Sotoodehnia N, Siscovick DS, Vatta M, Psaty BM, Tracy RP, Towbin JA, Lemaitre RN, Rea TD, Durda JP, Chang JM, Lumley TS, Kuller LH, Burke GL, Heckbert SR. β2-adrenergic receptor genetic variants and risk of sudden cardiac death. Circulation 2006; 113:1842-1848.
10. Stanzione R, Di Angelantonio E, Evangelista A, Barbato D, Marchitti S, Zanda B, Pirisi A, Quarta G, Volpe M, Rubattu S. β2-adrenergic receptor gene polymorphisms and risk of ischemic stroke. Am J Hypertens 2007; 20:657-662.
11. Lanfear DE, Jones PG, Marsh S, Cresci S, McLeod HL, Spertus JA. β2-adrenergic receptor genotype and survival among patients receiving β-blocker therapy after an acute coronary syndrome. JAMA 2005; 294:1526-1533.
12. Iwai C, Akita H, Kanazawa K, Shiga N, Terashima M, Matsuda Y, Takai E, Miyamoto Y, Shimizu M, Kajiya T, Hayashi T, Yokoyama M. Arg389Gly polymorphism of the human β1-adrenergic receptor in patients with nonfatal acute myocardial infarction. Am Heart J 2003; 146:106-109.
13. Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW, Wagner EH, Furberg CD. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274:620-625.
14. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993; 22:1189-1192.
15. Nickerson DA, Tobe VO, Taylor SL. PolyPhred: automating the detection and genotyping of single nucleotide substitutions using fluorescence-based resequencing. Nucleic Acids Res 1997; 25:2745-2751.
16. Carlson CS, Eberle MA, Rieder MJ, Yi Q, Kruglyak L, Nickerson DA. Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet 2004; 74:106-120.
17. Hosmer DW, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992; 3:452-456.
18. Liggett SB, Mialet-Perez J, Thaneemit-Chen S, Weber SA, Greene SM, Hodne D, Nelson B, Morrison J, Domanski MJ, Wagoner LE, Abraham WT, Anderson JL, Carlquist JF, Krause-Steinrauf HJ, Lazzeroni LC, Port JD, Lavori PW, Bristow MR. A polymorphism within a conserved β (1)-adrenergic receptor motif alters cardiac function and β-blocker response in human heart failure. Proc Natl Acad Sci USA 2006; 103:11288-11293.
19. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF. β 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther 2003; 74:44-52.
20. Liu J, Liu Z, Yu B, Zu F, Mo W, Zhou G, Liu Y, Li Q, Zhou H. β1-Adrenergic receptor polymorphisms influence the response to metoprolol monotherapy in patients with essential hypertension. Clin Pharmacol Ther 2006; 80:23-32.
21. Herrmann SM, Nicaud V, Tiret L, Evans A, Kee F, Ruidavets JB, Arveiler D, Luc G, Morrison C, Hoehe MR, Paul M, Cambien F. Polymorphisms of the β2-adrenoceptor (ADRB2) gene and essential hypertension: the ECTIM and PEGASE studies. J Hypertens 2002; 20:229-235.
22. Yamada Y, Izawa H, Ichihara S, Takatsu F, Ishihara H, Hirayama H, Sone T, Tanaka M, Yokota M. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347:1916-1923.
23. Hindorff LA, Heckbert SR, Psaty BM, Lumley T, Siscovick DS, Herrington DM, Edwards KL, Tracy RP. β (2)-Adrenergic receptor polymorphisms and determinants of cardiovascular risk: the Cardiovascular Health Study. Am J Hypertens 2005; 18:392-397.
24. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-2572.